Replies to post #789104 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

suit,

“What do they have to their name?” 😶



Fact ✅: There was a time in recent history when NWBO had only ONE asset…

Today, NWBO has FIVE+ asset categories. Shorts are finding their position more & more precarious with each step of progress.. that’s why we see the fud flood here 24/7

NWBO’s Assets Include:
⭐️ DCVax®-L & DCVax®-Direct
⭐️ Roswell DC platform(s)
⭐️ Flaskworks Eden technology
⭐️ In-licensed TLR agonist
⭐️ Fully licensed & operational in-house CDMO

NWBO also has some important approvals…

Fact ✅:
The MHRA has already awarded several approvals, including their approval of the MIA (a prerequisite of the MAA) & their ongoing support of the DCVax-L Specials Program.

Mar 2023, NWBO & Advent MIA Approval


Aug 2022, NWBO PIP Approval


Dec 2021, NWBO & Advent GMP License Approval



Regarding the P3, enrollment completed years before 2020, but patients continued to be treated & followed under the trial protocol as trial participants after enrollment closed. The P3 trial concluded in 2020, & data lock happened in Q4 of 2020…

COMBOS with checkpoint inhibitors & other agents are much more recent & have reached P2 for both DCVax-L & the Roswell DC technology platform.

⭐️Combo is King!⭐️



⭐️ Lifetime Achievement Award in Medicine, Dr. Liau

⭐️ AACR Advances in Ovarian Cancer Research

⭐️ NWBO to Acquire Advent BioServices

⭐️ Recent Conference

⭐️ DCVax-L Combo PII UCLA

⭐️ DC Combo PII Roswell Park

⭐️ 10-Q Quarterly Report

⭐️ 10-K Annual Report

⭐️ NICE UK 🇬🇧 DCVax-L

⭐️ ASM June 29, 2024

⭐️ Manufacturing Technology

⭐️ NWBO Acquires Flaskworks

⭐️ Roswell Park IP Portfolio

⭐️ TLR3 agonist Ampligen (rintatolimod)

⭐️ Next Generation Dendritic Cell Treatments





⭐️Combo is King!⭐️

AI Fact-Checking